Research programme: infectious diseases vaccines - iBio/Immunological Technology Institute

Drug Profile

Research programme: infectious diseases vaccines - iBio/Immunological Technology Institute

Alternative Names: Yellow fever vaccine - iBio/Immunological Technology Institute

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunobiological Technology Institute; Oswaldo Cruz Foundation
  • Class Recombinant proteins; Vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Yellow fever

Most Recent Events

  • 25 Jul 2016 Preclinical development is ongoing in Brazil (iBio pipeline, July 2016)
  • 17 Jun 2014 iBio, Bio-Manguinhos/Fiocruz and Fraunhofer USA Centre for Molecular Biotechnology expand their collaboration agreement for development of recombinant vaccines for Yellow fever
  • 19 Jan 2011 Preclinical trials in Yellow fever in Brazil (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top